Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Xthetix Inc.

This article was originally published in Start Up

Executive Summary

Xthetix is developing a handheld, high-frequency ultrasound device for the up-and-coming consumer aesthetic device market, leading with a product for treating and preventing acne. By heating skin tissue at a desired target depth without heating the skin's surface, its device can quickly treat existing pimples. Since it can also deposit heat directly into the sebaceous glands and hair follicles, it can inhibit the formation of sebum and thus prevent mild to moderate acne from erupting.

You may also be interested in...



Start-Up Previews (03/07)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group: Do-It-Yourself Dermatology, features profiles of Therative and Xthetix. Plus these Start-Ups Across Health Care: iCardiac Technologies, Jenken Biosciences, Neovasc Medical, and Syntaxin.

Do-It-Yourself Dermatology

As venture capitalists begin counting cosmetics and aesthetics companies as part of their portfolios, they're also migrating toward investing in consumer-oriented companies including those that make aesthetic devices to be used in the home.

Aesthetics: Noninvasive Fat Removal Enters the Scene

New energy-based fat removal technology is emerging as the next frontier in noninvasive energy-based aesthetics, but questions remain as to its mechanism of action in treating fat or cellulite. There is no question that patient demand is strong, and there are a number of products and techniques under development.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT037495

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel